TY - JOUR
T1 - Plasma neurofilament light chain (NfL) reference interval determination in an Age-stratified cognitively unimpaired cohort
AU - Bornhorst, Joshua A.
AU - Figdore, Daniel
AU - Campbell, Michelle R.
AU - Pazdernik, Vanessa K.
AU - Mielke, Michelle M.
AU - Petersen, Ronald C.
AU - Algeciras-Schimnich, Alicia
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Background and Aims: Neurofilament light chain (NfL) is an emerging biomarker of neurodegenerative disease progression. As plasma NfL increases with age, characterization of NfL concentrations in an age-stratified cognitively unimpaired population was assessed. Materials and Methods: EDTA-plasma samples were measured using the Simoa® NF-light™ Advantage Kit assay. One-sided reference intervals were established from 1100 cognitive normal individuals (588 male, 512 female) aged 20 to 95 years. Of those, 927 samples were obtained from the Mayo Clinic Study of Aging cohort (age > 50 years), and the remainder (age < 50 years) were obtained from individuals without known neurological conditions. All samples were from individuals without known chronic kidney disease, stroke or myocardial infarction, and a body mass index < 30 kg/m2. Results: The 97.5th percentile limits for the following age ranges (in years) were (pg/mL): 20 s: ≤8.4, 30 s: ≤11.4, 40 s: ≤15.4, 50 s: ≤20.8, 60 s: ≤28.0, 70 s: ≤37.9, 80+: ≤51.2. Sex had no significant effect on reference intervals. Observed NfL concentrations increased at a rate of 3.1 % per year of age. Conclusions: Characterization of the rate of NfL concentration increase and decade-wide reference intervals from a neurologically well-characterized patient population will aid in interpretation of NfL during the clinical evaluation of a potential neurodegenerative disease.
AB - Background and Aims: Neurofilament light chain (NfL) is an emerging biomarker of neurodegenerative disease progression. As plasma NfL increases with age, characterization of NfL concentrations in an age-stratified cognitively unimpaired population was assessed. Materials and Methods: EDTA-plasma samples were measured using the Simoa® NF-light™ Advantage Kit assay. One-sided reference intervals were established from 1100 cognitive normal individuals (588 male, 512 female) aged 20 to 95 years. Of those, 927 samples were obtained from the Mayo Clinic Study of Aging cohort (age > 50 years), and the remainder (age < 50 years) were obtained from individuals without known neurological conditions. All samples were from individuals without known chronic kidney disease, stroke or myocardial infarction, and a body mass index < 30 kg/m2. Results: The 97.5th percentile limits for the following age ranges (in years) were (pg/mL): 20 s: ≤8.4, 30 s: ≤11.4, 40 s: ≤15.4, 50 s: ≤20.8, 60 s: ≤28.0, 70 s: ≤37.9, 80+: ≤51.2. Sex had no significant effect on reference intervals. Observed NfL concentrations increased at a rate of 3.1 % per year of age. Conclusions: Characterization of the rate of NfL concentration increase and decade-wide reference intervals from a neurologically well-characterized patient population will aid in interpretation of NfL during the clinical evaluation of a potential neurodegenerative disease.
KW - Neurofilament light chain
KW - Neurological disease marker
KW - NfL
KW - Plasma
KW - Reference interval
UR - http://www.scopus.com/inward/record.url?scp=85138539307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138539307&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2022.08.017
DO - 10.1016/j.cca.2022.08.017
M3 - Article
C2 - 36041549
AN - SCOPUS:85138539307
SN - 0009-8981
VL - 535
SP - 153
EP - 156
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -